thrombopoietin receptor agonists in itp: current status and future outlooks
Published 1 year ago • 303 plays • Length 3:17Download video MP4
Download video MP3
Similar videos
-
1:32
shifting the treatment landscape of itp: novel agents and future outlooks
-
0:52
the role and clinical use of tpo receptor agonists in the treatment of itp
-
2:38
the management of itp during and after the covid-19 pandemic
-
1:59
novel investigational drugs and promising therapies for immune thrombocytopenia
-
1:54
fostamatinib and efgartigimod: novel agents in the treatment of itp
-
1:09
emerging treatment options for refractory immune thrombocytopenia
-
3:11
the therapeutic implications of shared pathophysiology in classical itp and other thrombocytopenias
-
1:28
differentiating immune thrombocytopenia from ipd and pid
-
3:47
a new form of inherited thrombocytopenia: etv6, never judge a book by its cover
-
1:26
avatrombopag, rilzabrutinib and covid-19 updates in itp
-
4:10
thrombopoietin receptor agonists
-
1:55
latest updates in the management of immune thrombocytopenia
-
4:20
itp update: diagnosis, treatment & covid-19 vaccines
-
2:03
unmet needs in immune thrombocytopenia
-
3:26
the risk of thrombotic events in patients with mgus: an analysis from the istopmm trial
-
1:19
the potential of caplacizumab in the treatment of attp
-
2:51
ruxolitinib in combination with abemaciclib for patients with primary or post-pv/et myelofibrosis
-
2:11
thrombopoietin receptor agonist
-
1:28
phase i study of pevonedistat and ibrutinib in r/r b-nhl